Actively Recruiting
Study to Estimate Seedchrony's Predictive Capacity in the Success of Embryo Implantation.
Led by Manina Medtech · Updated on 2024-11-27
80
Participants Needed
1
Research Sites
70 weeks
Total Duration
On this page
Sponsors
M
Manina Medtech
Lead Sponsor
H
Hospital Universitari Vall d'Hebron Research Institute
Collaborating Sponsor
AI-Summary
What this Trial Is About
In Vitro Fertilization (IVF) success is below 40%, with Embryo Transfer the leading cause of IVF failure. This clinical investigation aims to evaluate if the levels of an intrauterine biomarker dissolved in the uterine fluid (alone or as a complex biological marker) can predict the outcome of embryo transfer.
CONDITIONS
Official Title
Study to Estimate Seedchrony's Predictive Capacity in the Success of Embryo Implantation.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- First IVF cycle patients
- Patients who sign the informed consent form
- Patients between 18 and 37 years old
- Patients BMI 64 30
- Patients who have frozen blastocysts of good quality (grade A or B)
- Patients with negative vaginal and endocervical cultures
- Patients with an antimullerian hormone level greater than 1 ng/mL
- IVF patients with an endometrial thickness greater than 7mm with trilaminar pattern on the day of the pre-progesterone visit
- Patients who have not had a previous embryo transfer or have failed only one embryo transfer
You will not qualify if you...
- Patients with seminal data of the couple showing severe oligozoospermia (sperm concentration <1 million sperm per ml) or azoospermia (absence of sperm in the ejaculate)
- Patients diagnosed with uterine pathologies such as endometriosis, cancer, malformations, untreated polyps, or submucous fibroids
- Patients diagnosed with medical conditions including Polycystic ovary syndrome (PCOS), insulin-dependent diabetes mellitus, Cushing's syndrome, uncorrected thyroid dysfunction, hepatic and/or renal insufficiency, contraindication to ovarian stimulation or pregnancy, antiphospholipid syndrome, or autoimmune disease
- Patients currently taking medications other than contraceptives that may affect fertility or menstrual cycle regulation
- Patients with a history or evidence of drug, tobacco, or alcohol abuse or dependence
- Patients with inadequate understanding of spoken and written Spanish
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Vall d'Hebron Hospital
Barcelona, Other (Non US), Spain, 08035
Actively Recruiting
Research Team
M
Monica Rodriguez de la Vega, PhD
CONTACT
L
Luis Artiles, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here